Advertisements

Sertralina Stada

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sertralina Stada

Property Description
Active Ingredient Sertraline (as Hydrochloride)
Form Film-coated tablets
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Mood regulation and stabilization
Origin Synthetic compound

What Type of Medicine is Sertralina Stada?

Sertralina Stada is a synthetic, prescription-only medication classified as an antidepressant. Its single active ingredient is Sertraline, which is specifically categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). As a branded generic medicine, Sertralina Stada contains the same pharmacologically active substance, Sertraline, as the original innovator product, distinguishing it by its specific manufacturer and market authorization. The designation SSRI indicates that the drug's mechanism is highly selective, differentiating it from older psychoactive medications that target a broader array of neurotransmitter systems. The primary chemical structure of Sertraline is derived from naphthalenamine, confirming its manufactured origin as a synthetic compound.

Sertraline: Composition and General Therapeutic Purpose

The medicine is manufactured as a film-coated tablet, an oral solid dosage form designed for oral administration (by mouth). This format ensures a precise and consistent quantity of the Sertraline Hydrochloride active ingredient is delivered. The fundamental therapeutic purpose of Sertraline is linked directly to its SSRI classification: it is clinically recognized for its ability to regulate mood and emotional stability by influencing the brain's monoamine neurotransmitter signaling. It achieves this via serotonin reuptake blockade, an action which effectively increases the concentration and duration of the serotonin neurotransmitter in the spaces between nerve cells, thereby stabilizing the patient’s emotional equilibrium.

Regulatory References

  1. WHO Essential Medicines List for Sertraline
Advertisements

What side effects are possible with Sertralina Stada?

Possible side effects and safety information

Adverse reactions associated with this medicine are organized by regulatory authorities based on the affected System Organ Class and their reported frequency (e.g., Very Common, Common). This classification helps define the official safety profile.

The most frequently reported reactions, classified as Very Common (ge 1/10), primarily involve the Gastrointestinal and Nervous System domains, and include Nausea, Diarrhoea, Insomnia, Headache, and Dizziness. Other common reactions (ge 1/100 to <1/10) include Tremor, Dry mouth, Ejaculation failure, Fatigue, and changes in Appetite or Weight.

Serious Adverse Reactions and Restrictions

Official labeling documents several serious adverse reactions. The risk of Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like events is a high-level safety concern, especially when used with other serotonergic agents. Consequently, concomitant use with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated.

A significant regulatory warning addresses the potential for Suicidal Ideation and Behaviour, particularly at the beginning of treatment and during dose changes, a risk noted to be greater in the paediatric and young adult populations. Other serious documented risks include Hyponatraemia (low sodium), which is noted to be a greater consideration in older adults, and the potential for QT-interval prolongation (a change in heart rhythm).

For patients with Hepatic impairment, caution is necessary, and use in individuals with severe liver disease may be restricted due to altered drug elimination. Adverse effects may be more frequent at the start of treatment and often lessen with continued use, according to regulatory data.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The information below describes the official, regulator-documented overdose profile and the actions mandated by government health authorities.

Overdose scope

Property Description
Documented overdose presentations Symptoms documented in regulatory sources include somnolence, agitation, tremor, tachycardia (rapid heart rate), and gastrointestinal disturbances (nausea, vomiting).
Physiological systems affected Central Nervous System (CNS), Cardiovascular System, and Gastrointestinal System.
Exposure-related factors Increased severity, including fatalities, is frequently associated with co-ingestion with other drugs and/or alcohol.
Emergency-response statements The mandated action is to seek immediate medical attention for any suspected overdose. Management is limited to symptomatic and supportive treatment.

Overdose classifications (high-level)

Property Description
Severity classification Outcomes range from commonly reported mild symptoms to life-threatening events, including Serotonin Syndrome, seizures, and cardiac effects (e.g., QTc prolongation).
Antidote status Regulatory documents explicitly state that no specific antidote to Sertraline is known.

Resulting overdose structure

Official overdose statements:

  • Seek immediate medical attention right away if severe signs like collapse, seizure, or trouble breathing occur.
  • Cardiac (ECG) and vital sign monitoring are required during hospital management.
  • Procedures such as forced diuresis, dialysis, or emesis induction are officially described as unlikely to be of clinical benefit.

Connection to the overall overdose profile: Regulatory documents define the Sertraline overdose profile by listing the full spectrum of observed manifestations and mandating immediate emergency medical care for any suspected event. The official strategy relies on urgent recognition of life-threatening signs and regulator-approved supportive intervention procedures, as no specific antidote is available. This profile underscores the need to contact emergency services for any severe or unexpected manifestation.

Advertisements

Therapeutic Uses of Sertralina Stada

What Sertralina Stada Treats: Main Uses and Benefits

Sertralina Stada is used to manage symptomatic domains where emotional tension, low mood, or intrusive thought patterns may become more disruptive. Sertraline is used for managing a range of severe mood and anxiety-related conditions.

The medication may be part of symptomatic management across conditions characterized by periods of heightened symptoms, including Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and the severe mood fluctuations of Premenstrual Dysphoric Disorder (PMDD). This comprehensive approach is relevant when supportive symptom management is appropriate, particularly during acute episodes or long-term maintenance.

The medication may assist with managing the intensity of sudden fear attacks, is relevant for easing pervasive sadness, and supports the handling of distressing manifestations. This use contributes to easing the overall symptom load and may assist with maintaining functional stability.


Quick Fact: Symptom Management in Pervasive Low Mood
Sertraline supports patients during difficult episodes by easing distress and is applied in addressing the symptom cluster of persistent sadness and loss of interest associated with Major Depressive Disorder.

Regulatory References

  1. U.S. National Institutes of Health (NIH) StatPearls
Advertisements

Eligibility and Restrictions for Use

Sertralina Stada use is strictly defined by regulatory eligibility criteria. The medicine is contraindicated in patients with a known hypersensitivity to the drug or any of its excipients. It must not be used concurrently with an irreversible Monoamine Oxidase Inhibitor (MAOI), including linezolid, or the medicine pimozide, due to the risk of severe reactions.

The medicine is approved for adults (18 and over) for all registered indications. Use in pediatric patients (6 to 17 years) is restricted to Obsessive Compulsive Disorder (OCD); use for non-OCD indications is not approved in this age group. The official label includes a warning regarding the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients under the age of 25.

Eligibility is also restricted by physiological status. Use is not recommended for patients with severe hepatic impairment. Use with caution is necessary in patients with mild to moderate hepatic impairment. The labeling also advises caution for those with a history of mania/hypomania, unstable epilepsy, or untreated narrow-angle glaucoma. Patients with renal impairment typically require no specific dose adjustment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sertralina Stada (Sertraline) is formally documented in regulatory sources and primarily involves pharmacokinetic (PK) and pharmacodynamic (PD) interaction types.

Formal Restrictions and Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including irreversible MAOIs and the reversible MAOIs Linezolid and intravenous Methylene Blue, is strictly contraindicated. A mandatory washout period of 7 to 14 days is required when transitioning between Sertraline and MAOIs. Co-administration with Pimozide is also prohibited, as Sertraline can increase its plasma concentration.

Pharmacokinetic and Exposure-Modifying Interactions

Sertraline is officially classified as a moderate inhibitor of the CYP2D6 enzyme. This pharmacokinetic interaction can lead to an increase in the plasma exposure of co-administered CYP2D6 substrates, such as Tricyclic Antidepressants (TCAs). Separately, co-administration with Cimetidine is documented to result in a decrease in Sertraline clearance. For patients with hepatic impairment, Sertraline clearance is reduced, which results in approximately two-fold greater exposure to the active metabolite.

Pharmacodynamic and Substance Interactions

Combining Sertraline with other serotonergic agents (e.g., Triptans or certain opioids) creates an additive pharmacodynamic risk of heightened serotonergic load. Co-administration with antiplatelet drugs (e.g., NSAIDs, Aspirin) or anticoagulants (e.g., Warfarin) increases the officially documented risk of bleeding. Additionally, taking the tablet formulation with food increases the maximum plasma concentration (C max) by 25%.

Advertisements

Mechanism of Action

Selective Blockade of the Serotonin Transporter

This core mechanism involves the high-affinity inhibition of the Serotonin Transporter (SERT), the protein responsible for clearing the neurotransmitter serotonin (5-HT) from the synapse. By selectively blocking this reuptake process, the drug immediately increases the concentration and duration of 5-HT signaling in the central nervous system. This direct action on the SERT defines the drug's primary pharmacological class, initiating the cascade that leads to altered neural pathway activity.


The Delayed Process of Cellular Adaptation

The full physiological effect is not immediate because the mechanism relies on a slow, adaptive response: the desensitization and downregulation of pre-synaptic inhibitory autoreceptors. This long-term change removes the initial "brake" on 5-HT release, enabling a sustained and amplified serotonergic signal across regulatory brain circuits. This cumulative process, often coupled with the upregulation of neuroplasticity factors like BDNF, is what ultimately leads to the functional modulation of CNS pathways involved in emotional processing and the remodeling of neuronal activity within key regulatory circuits.


Mechanism Constraints on Functional Onset

The functional mechanism is fundamentally constrained by the time required for this cellular adaptation to occur, meaning the physiological consequences are delayed by several weeks despite the rapid molecular action. Furthermore, the drug's action is primarily limited to the parent compound itself, Sertraline, as its major metabolite exhibits significantly lower affinity for SERT inhibition.

Advertisements

Dosage and Administration Information

Sertralina Stada is a medication delivered exclusively via the oral route as a film-coated tablet. The usage pattern is defined by a once-daily schedule, which may be administered at a consistent time each day, irrespective of food intake.

Standardized Dosing and Titration

The use of Sertraline follows a standardized titration schedule. Treatment typically starts with a dose of 25 mg (for certain anxiety-related disorders) or 50 mg (for depression and Obsessive-Compulsive Disorder). The dose is then increased gradually using 25 mg or 50 mg increments, with a minimum interval of one week between adjustments.

This titration is required for establishing a stable maintenance dose, which must not exceed the maximum recommended daily limit of 200 mg for most approved uses.

Administration Context and Adjustments

Modifications are utilized for specific populations. Patients diagnosed with mild hepatic impairment use a lower starting and maximum dosage, typically half the usual amount, due to altered clearance. In contrast, no specific dosage adjustment is mandated based solely on renal impairment.

If a scheduled daily dose is missed, the standard procedure is to skip the missed dose and take the next dose at the regularly scheduled time, rather than attempting to double the dose. The overall course of therapy is defined as long-term and must conclude with a gradual dose reduction (tapering), which is necessary to complete the usage protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sertralina Stada

Evidence for Major Depressive Disorder (MDD)

Research exploring Major Depressive Disorder (MDD) primarily relies on short-term Randomized Controlled Trials (RCTs). These studies are used in research exploring how symptoms change over time and typically measure symptom intensity using standardized rating scales, with observation periods generally lasting 8 to 12 weeks. Evidence also provides insight into symptom patterns in longer-term maintenance studies that research examined outcomes related to continuation of treatment for up to one year to observe patterns of symptom return. However, evidence is limited for certain groups; for instance, some research reported mixed findings or limited early score changes in specific adult populations.

Evidence for Anxiety, Trauma, and Related Disorders

A substantial body of research has studied for this medication across conditions related to anxiety and trauma. These studies, mostly short-term RCTs, research examined outcomes reflecting daily functioning and outcomes capturing phases of heightened symptom activity.

Studies for Obsessive-Compulsive Disorder (OCD)

The evidence base for OCD includes controlled studies in both adult and pediatric patients. Researchers focused on outcomes reflecting daily functioning, using specialized scales to measure observed change in the intensity of obsessive thoughts and compulsive behaviors. Follow-up durations were limited in these acute trials, meaning that long-term outcomes for symptom evolution are more commonly described in continuation studies.

Studies for Post-Traumatic Stress Disorder (PTSD)

Research for PTSD has been conducted during periods of increased symptom activity in adult populations, utilizing RCTs. Studies monitored change across the specific symptom clusters of PTSD, such as re-experiencing and avoidance. Maintenance studies also explored outcomes related to monitoring patterns of symptom return.

Research in Specific and Special Populations

Studies have explored the medication in specific patient cohorts beyond the general adult population. For instance, research examined pediatric patients for MDD and OCD. Other studies were observed in specific adult cohorts, such as patients who have experienced a traumatic brain injury (TBI), to assess patterns related to symptoms in that context. Results apply only to the populations studied, and evidence is limited for certain groups, with limited information available to characterize outcomes across all possible subgroups or conditions.

Summary of Evidence Gaps and Uncertainties

This section will synthesize the main evidence gaps and limitations documented in the scientific and regulatory literature, clarifying areas where long-term data is limited or where outcomes were reported as heterogeneous or inconsistent across different populations.

Key Studies & References

  1. Sertraline - StatPearls (NIH National Library of Medicine)
  2. Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sertralina Stada (FAQ)

Q: What is Sertralina Stada primarily used for?

A: According to official product information, Sertraline is approved to treat several conditions. These include Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Post-Traumatic Stress Disorder (PTSD). It is also approved for Social Anxiety Disorder (SAD) and Premenstrual Dysphoric Disorder (PMDD).

Q: Is Sertralina Stada the same type of medicine as Fluoxetine?

A: Sertraline is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Regulatory documents have noted that the drug belongs to the same class of antidepressants as Fluoxetine. Studies indicate that Sertraline's overall efficacy profile is similar to that of other SSRI antidepressants.

Q: Is it normal to feel more anxious when first starting Sertralina Stada?

A: Yes, regulatory documents list anxiety and agitation as adverse reactions that are commonly reported by patients. These feelings may be experienced, particularly when a person first begins treatment with the medication. This is documented as a possible effect during the initial phase of therapy.

Q: Can Sertralina Stada cause changes in sleep patterns?

A: The official product information states that changes in sleep habits are common side effects. These changes can manifest as difficulty sleeping (insomnia) or as increased sleepiness (somnolence). Abnormal dreams, including vivid dreams, are also listed as a reported side effect.

Q: Is it true that Sertralina Stada can cause weight changes?

A: Yes, changes in body weight are listed in official documents as a possible side effect. Clinical trials have reported both a loss of appetite and weight gain among patients taking the medication.

Q: Are there any common foods or drinks that should be avoided while taking Sertralina Stada?

A: Official regulatory information advises that co-consumption with grapefruit or grapefruit juice is not recommended. This is because it may increase the concentration of Sertraline in the body, potentially leading to increased side effects. The Sertraline tablet formulation may otherwise be taken with or without food.

Q: Are there different brand names that contain the same active ingredient as Sertralina Stada?

A: Yes. The active ingredient in Sertralina Stada is Sertraline. This same ingredient is marketed under multiple brand names globally, with Zoloft being one of the major brands, in addition to several generic versions.

Q: What are the main differences between Sertralina Stada and other SSRIs?

A: Official comparative studies indicate that Sertraline has a similar efficacy profile to other SSRIs when treating approved conditions. However, differences may exist in their respective side-effect and tolerability profiles, meaning some patients may respond differently to one SSRI compared to another.

Q: Is Sertralina Stada commonly prescribed for conditions other than depression?

A: Yes. Regulatory documents state that Sertraline is approved to treat several other conditions besides depression, including Panic Disorder, PTSD, Social Anxiety Disorder, and Obsessive-Compulsive Disorder. These conditions represent its approved uses based on clinical evidence.

Q: Does Sertralina Stada show up on common drug tests?

A: Reports indicate that Sertraline may lead to false-positive results in certain urine screening tests, such as those for benzodiazepines. Official guidance suggests confirmatory testing is generally a prudent measure if a positive result is obtained.

Q: Can Sertralina Stada affect a person's ability to drive or operate machinery?

A: The product label includes warnings that Sertraline may cause dizziness, drowsiness, or other side effects that can impair judgment. Regulatory warnings advise patients to understand how the medication affects them before engaging in activities like driving or operating complex machinery.

Q: Are there restrictions on using alcohol while on Sertralina Stada?

A: Official information generally advises against the use of alcohol during treatment with Sertraline. Combining alcohol with the medication may worsen central nervous system side effects, such as dizziness and drowsiness.

Q: Do studies suggest Sertralina Stada is effective for treating panic disorder?

A: Sertraline is an FDA-approved treatment for Panic Disorder, which confirms that robust clinical studies have established its efficacy for this use in adults.

Q: Is there research evidence about the long-term use of Sertralina Stada?

A: Clinical trials detailed in regulatory documents include long-term continuation phases. These studies, such as one lasting 44 weeks, are designed to establish the drug's effectiveness in preventing the relapse of Major Depressive Disorder during ongoing, extended use.

Q: What is the risk of side effects if someone takes Sertralina Stada for an extended time?

A: Official data provides information on the frequency of side effects across both short-term and longer-term clinical trials. Long-term use has been studied, particularly concerning the lower rate of relapse observed for certain approved conditions in clinical trials.

Q: Is it normal to have vivid dreams when taking Sertralina Stada?

A: Official documents list abnormal dreams, including nightmares, as reported side effects. Changes in sleep patterns are commonly reported adverse effects of the medication.

Q: Can Sertralina Stada be taken while breastfeeding?

A: Regulatory warnings indicate that Sertraline is excreted in human breast milk. Due to this transfer, the official product information notes that the effects of the drug on a breastfed infant are not fully established.

Q: What is the typical experience of discontinuation symptoms when stopping Sertralina Stada?

A: Symptoms reported upon abrupt cessation or rapid dose reduction include dizziness, sensory disturbances, and sleep disturbances. Official product information states that treatment must be discontinued with a gradual dose reduction (tapering) to help manage the risk of these effects.

Q: How does Sertralina Stada interact with herbal supplements like St. John's Wort?

A: Regulatory documents state that co-administration with St. John’s Wort is not recommended. This is because this combination may increase the risk of a rare but serious condition known as serotonin syndrome, which results from an excessive level of serotonin in the body.

Q: Is Sertralina Stada considered habit-forming or addictive?

A: Sertraline is not classified as a controlled substance and official data indicates it has not been associated with drug abuse. However, regulatory instructions state that treatment must conclude with a gradual dose reduction (tapering) to manage the risk of physical dependence and potential withdrawal effects.

Q: Are there specific symptoms that require immediate medical attention while on Sertralina Stada?

A: Yes. Serious side effects that may require immediate medical attention are symptoms of serotonin syndrome, such as agitation, fast heart rate, and hallucinations. Severe allergic reactions (like rash or swelling) and unusual bleeding or bruising are also considered critical warnings in regulatory documents.

Q: Can men experience sexual side effects when taking Sertralina Stada?

A: Sexual dysfunction is listed as a common side effect of Sertraline. For men, this can include decreased libido (sex drive), difficulty achieving orgasm, and ejaculation failure. This effect is documented in the official product information.

Q: What are the reported effects of Sertralina Stada on blood pressure?

A: Clinical trial data lists both high blood pressure (hypertension) and low blood pressure (hypotension) as possible adverse reactions. These cardiovascular effects are generally considered less common than other reported side effects.

Q: Why do doctors recommend continuing Sertralina Stada even after feeling better?

A: Clinical evidence documented in regulatory sources established the drug's effectiveness in preventing the relapse of Major Depressive Disorder (MDD). This finding justifies continued therapy for patients who have responded well to the initial treatment phase.

Q: What is the active ingredient in Sertralina Stada?

A: The active ingredient in Sertralina Stada is Sertraline. It is most commonly marketed and provided in a salt form, known as Sertraline hydrochloride.

Q: Is Sertralina Stada used for social anxiety disorder?

A: Yes. Regulatory documents confirm that Sertraline is an approved treatment for Social Anxiety Disorder (SAD) in adults. The drug’s efficacy for this condition has been established through clinical trials.

Q: Can taking Sertralina Stada affect fertility?

A: Pre-clinical studies and some regulatory text have raised concerns about the potential effects of the drug on semen quality. While not a definitive claim, this may affect fertility in some patients and is a matter of caution in official guidance.

Q: What are the differences in how Sertralina Stada and Bupropion (Wellbutrin) work?

A: Sertraline works by selectively blocking the reuptake of serotonin (5-HT), which classifies it as an SSRI. Bupropion, in contrast, belongs to a different drug class and primarily affects the reuptake of the neurotransmitters norepinephrine and dopamine.

Q: Are there any patient populations for whom Sertralina Stada is generally not recommended?

A: The medication is strictly contraindicated for use with MAOIs (Monoamine Oxidase Inhibitors) and Pimozide. Additionally, the product label carries a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) when beginning treatment.

Q: Can Sertralina Stada cause dry mouth?

A: Yes. Dry mouth is documented as a common side effect in the official product information. This effect is one of the more frequently reported adverse reactions.

Q: Is it common to experience nausea when first beginning Sertralina Stada treatment?

A: Yes. Nausea is reported in official documents as one of the most common adverse reactions experienced by patients. This effect is often reported during the period when treatment is first initiated.

Q: What kind of research has been conducted on Sertralina Stada and its main uses?

A: The drug’s approval is based on results from short-term (6- to 12-week) placebo-controlled clinical studies establishing acute efficacy for its approved uses. Research also includes longer-term studies focused on relapse prevention and safety over time.

Q: Do official documents mention any potential for drug dependence with Sertralina Stada?

A: Official documents indicate that the body develops a physical dependence on the drug over the course of treatment, even though it is not considered a drug of abuse. For this reason, official guidance requires a gradual dose reduction to manage potential withdrawal symptoms.

Q: What information is available about Sertralina Stada's use during pregnancy?

A: Regulatory sources advise that use during the late stages of pregnancy (the third trimester) is generally not recommended. Use during this period may be associated with an increased risk of complications for the newborn, such as persistent pulmonary hypertension.

Q: What are the potential signs of an allergic reaction to Sertralina Stada?

A: Signs of a serious allergic reaction that are documented include skin rash, hives, and swelling of the face, lips, tongue, or throat. Difficulty breathing is also listed as a potential emergency symptom that requires attention.

Q: Is Sertralina Stada available as a generic drug?

A: Yes. The active substance, Sertraline, is widely available as a generic medication. Generic versions contain the same active ingredient as the brand-name product.

Q: Is Sertralina Stada used to treat generalized anxiety disorder (GAD)?

A: Generalized Anxiety Disorder (GAD) is listed in official documents as a condition for which Sertraline is an approved treatment in some countries. Its use for this condition is based on clinical evidence.

Q: Can Sertralina Stada cause changes in appetite?

A: Changes in appetite are documented as a common adverse effect in official product information. This effect can include both increased and decreased appetite, which may consequently lead to changes in body weight.

Q: Are there any specific safety warnings related to teenagers taking Sertralina Stada?

A: The product label contains a Boxed Warning regarding the increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (under 25). This warning applies specifically during the initial phase of treatment or following dose changes.

Q: Do women experience different side effects from Sertralina Stada compared to men?

A: While many common side effects are similar across sexes, there are specific differences. Adverse reactions like ejaculation failure are unique to men, and the drug is also indicated for Premenstrual Dysphoric Disorder (PMDD) in women, highlighting some sex-specific effects.

Q: What are the high-level research findings on Sertralina Stada and PTSD (Post-Traumatic Stress Disorder)?

A: Sertraline is an FDA-approved treatment for Post-Traumatic Stress Disorder (PTSD) in adults. This approval indicates that the clinical trials conducted established the drug’s effectiveness for this condition.

Q: Is it necessary to have regular check-ups while taking Sertralina Stada?

A: Regulatory guidance emphasizes the need for close observation and frequent communication with the prescriber. This is deemed necessary, especially when starting the drug or when the dosage is being adjusted.

Q: Can Sertralina Stada cause headaches?

A: Yes. Headache is documented as a common side effect in the official product information. It is one of the frequently reported adverse reactions from clinical trials.

Q: Can Sertralina Stada be used by elderly people?

A: Sertraline is prescribed for elderly patients. However, official guidance advises caution due to the potential for lower sodium levels (hyponatremia) and the greater likelihood of age-related issues such as liver impairment affecting the body's clearance of the drug.

Q: Why is Sertralina Stada sometimes used to treat OCD (Obsessive-Compulsive Disorder)?

A: The drug is officially approved for the treatment of Obsessive-Compulsive Disorder (OCD) in both adults and pediatric patients. This use is based on evidence from controlled clinical trials that established its efficacy for OCD.

Q: How long after stopping Sertralina Stada do the medicine's effects last in the body?

A: Official pharmacokinetic data indicates that the active ingredient, Sertraline, has an elimination half-life of approximately 26 hours. However, its major metabolite remains in the body for a significantly longer period, with a half-life of 62 to 104 hours.

Q: Are there any restrictions for people with a history of seizures who are considering Sertralina Stada?

A: Regulatory warnings state that Sertraline must be used with caution in patients with a history of epilepsy or seizures. Official guidance requires discontinuation of the medication if any patient develops seizures during treatment.

Q: Can Sertralina Stada be taken at the same time as cold or flu medications?

A: The regulatory label generally warns against using Sertraline with other serotonergic agents. Because some cold or flu medications may contain ingredients that also affect serotonin levels, this combination may create a potential risk for an additive serotonergic effect.

Advertisements

How should Sertralina Stada be stored and disposed of?

How to Store and Dispose of Sertraline Tablets

Sertraline tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be kept in the original container with the cap tightly closed to protect it from excessive heat and moisture, and should be kept out of the reach and sight of children.

Disposal

Disposal of unused or expired tablets should prioritize an authorized drug take-back program. If a program is unavailable, and the drug is not on the FDA flush list, it should be mixed with an undesirable substance (such as dirt) and placed in a sealed container before being discarded in the household trash. It must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertralina Stada found in:

A-Z Index: